Chemed CORP Form 4 insider transactions

Brian C Judkins, VP and Chief Legal Officer of Chemed Corp, reported multiple transactions in common stock on August 10, 2026.

Joel L Wherley, CEO - Vitas Healthcare of Chemed Corp, reported multiple transactions in common stock on August 5, 2026.

Kevin J Mcnamara, president and CEO and a Director of Chemed Corp, sold 2,000 shares of common stock on July 31, 2026 for $539.51 per share.

Patrick P Grace, a Director of Chemed Corp, sold 190 shares of common stock on July 31, 2026 for $532.00 per share.

Chemed Corp Director Andrea R. Lindell reported the acquisition of 1,347 shares of capital stock.

Director George J. Walsh III sold 500 shares of Chemed Corp common stock at a price of $437.83 per share.

Chemed Corp director George J. Walsh III acquired 386 shares of company stock on May 18, 2026, valued at $440.77 per share.

Chemed Corp Director John Meredith Mount Jr. acquired 386 shares of capital stock.

Eileen P. McCarthy, a Director at CHEMED CORP, reported the acquisition of 386 shares of Capital Stock on May 18, 2026.

Chemed Corp Director Andrea R. Lindell acquired 386 shares of capital stock on May 18, 2026, increasing her direct beneficial ownership.

Chemed Corp director Christopher J. Heaney acquired 386 shares of company stock on May 18, 2026, valued at $440.77 per share.

Patrick P. Grace, a Director at Chemed Corp, reported the acquisition of 386 shares of company stock on May 18, 2026.

Ron DeLyons, a Director at Chemed Corp, reported the acquisition of 386 shares of company stock on May 18, 2026.

Director Patrick P. Grace sold 60 shares of Chemed Corp common stock at a price of $425.78 per share.

Kevin J. McNamara, President and CEO of Chemed Corp, reported a sale of 2,000 shares of capital stock on May 1, 2026.

Chemed Corp CEO and director Kevin J. McNamara sold 1,500 shares at a $369.37 weighted average on March 27, 2026, and now holds 92,219 shares directly.

CHEMED Corp's President and CEO, Kevin J. McNamara, sold 2,000 shares of company stock for a weighted average price of $403.18 per share.

CHEMED Corp's VP and Chief Legal Officer, Brian C. Judkins, acquired shares from vested performance stock units and received a new grant of PSUs, while also having shares withheld for taxes.

CHEMED Corp. Director Andrea R. Lindell reported gifting 463 shares of company capital stock, reducing her direct beneficial ownership to 5,539 shares.

CHEMED Corp's President and CEO, Kevin J. McNamara, sold 2,000 shares of company capital stock at a weighted average price of $437.55.

CHEMED Executive Vice President Spencer S. Lee reported gifting 60 shares of company capital stock on November 19, 2025.

CHEMED Corp. CEO of Vitas Healthcare, Joel L. Wherley, was granted 17,476 stock options with an exercise price of $443.79, vesting over three years.

CHEMED Corp's Executive Vice President, Spencer S. Lee, acquired 12,759 stock options with an exercise price of $443.79 under a Rule 10b5-1 plan.

CHEMED Corp.'s VP and Chief Legal Officer, Brian C. Judkins, was granted 15,017 stock options with an exercise price of $443.79, vesting over three years.

CHEMED Corp.'s VP & Chief Financial Officer, Michael D. Witzeman, was granted 19,486 stock options with an exercise price of $443.79, vesting over three years.

CHEMED Corp. Vice President Thomas C. Hutton acquired 6,338 stock options with an exercise price of $443.79, vesting annually starting October 21, 2026.

CHEMED Corp. President and CEO Kevin J. McNamara was granted 58,672 stock options at an exercise price of $443.79, vesting over three years.

CHEMED Corp.'s President and CEO, Kevin J. McNamara, reported the sale of 3,000 shares of company capital stock on September 26, 2025, under a Rule 10b5-1 trading plan.

CHEMED Corp. Director Patrick P. Grace sold 150 shares of common stock for $463.39 per share on September 9, 2025, under a Rule 10b5-1 plan.

CHEMED Corp's President and CEO, Kevin J. McNamara, sold 2,000 shares of company capital stock on August 5, 2025, for a weighted average price of $428.55 per share.